324 related articles for article (PubMed ID: 36712872)
1. Cell death-related biomarker SLC2A1 has a significant role in prognosis prediction and immunotherapy efficacy evaluation in pan-cancer.
Wang Y; Wang K; Zhang H; Jia X; Li X; Sun S; Sun D
Front Genet; 2022; 13():1068462. PubMed ID: 36712872
[No Abstract] [Full Text] [Related]
2. Glycolysis-Related SLC2A1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
Zheng H; Long G; Zheng Y; Yang X; Cai W; He S; Qin X; Liao H
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358765
[TBL] [Abstract][Full Text] [Related]
3.
Wang Y; Wen H; Sun D
Ann Transl Med; 2022 May; 10(9):519. PubMed ID: 35928739
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis identifies RNF43 as a prognostic, therapeutic and immunological biomarker.
Xu Y; Lin Z; Ji Y; Zhang C; Tang X; Li C; Liu T
Eur J Med Res; 2023 Oct; 28(1):438. PubMed ID: 37848933
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis of CREB3L1 as biomarker in the prediction of prognosis and immunotherapeutic efficacy.
Lin Z; Wu Y; Xiao X; Zhang X; Wan J; Zheng T; Chen H; Liu T; Tang X
Front Genet; 2022; 13():938510. PubMed ID: 36171879
[No Abstract] [Full Text] [Related]
7. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract][Full Text] [Related]
8. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
9. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
Front Immunol; 2022; 13():998266. PubMed ID: 36248785
[TBL] [Abstract][Full Text] [Related]
10. Integrated single-cell and bulk sequencing analyses with experimental validation identify the prognostic and immunological implications of CD226 in pan-cancer.
Ma P; Sun W
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14597-14617. PubMed ID: 37580402
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive pan-cancer analysis reveals CCDC58 as a carcinogenic factor related to immune infiltration.
Wu H; Geng Q; Shi W; Qiu C
Apoptosis; 2024 Apr; 29(3-4):536-555. PubMed ID: 38066393
[TBL] [Abstract][Full Text] [Related]
13.
Wu G; Chen M; Ren H; Sha X; He M; Ren K; Qi J; Lin F
Front Cell Dev Biol; 2022; 10():930933. PubMed ID: 35874816
[No Abstract] [Full Text] [Related]
14. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
[TBL] [Abstract][Full Text] [Related]
15. ERH Impacts Patient Prognosis and Tumor Immune Microenvironment: A Pan-Cancer Analysis.
Gong Q; Li Q; Shen X; Xu Z
Comb Chem High Throughput Screen; 2024 Apr; ():. PubMed ID: 38584561
[TBL] [Abstract][Full Text] [Related]
16. Pan-cancer analysis of the disulfidptosis-related gene
Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis reveals NAA50 as a cancer prognosis and immune infiltration-related biomarker.
Fang T; Wang D; Li R; Yu W; Tian H
Front Genet; 2022; 13():1035337. PubMed ID: 36568377
[No Abstract] [Full Text] [Related]
18. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
19. LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.
Luo L; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Hong S
Front Immunol; 2023; 14():959868. PubMed ID: 36798137
[TBL] [Abstract][Full Text] [Related]
20. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
Front Oncol; 2022; 12():998336. PubMed ID: 36185230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
